Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow

Best PFS In Second Line Setting

 
• By Andrew McConaghie
Sanofi Lyon
Sanofi's Sarclisa is taking on the $6bn-a-year blockbuster Darzalex. • Source: Alamy

More from Business

More from Scrip